KALA trades 3158.9% below Wall Street's consensus target of $18.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KALA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, KALA BIO, Inc. (KALA) has a Wall Street consensus price target of $18.25, based on estimates from 9 covering analysts. With the stock currently trading at $0.56, this represents a potential upside of +3158.9%. The company has a market capitalization of $11M.
Analyst price targets range from a low of $1.50 to a high of $35.00, representing a 184% spread in expectations. The median target of $18.25 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, KALA trades at a trailing P/E of -0.2x. Analysts expect EPS to grow -362.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 OCULOcular Therapeutix, Inc. | $2.2B | $10.00 | $27.50 | +175.0% | Buy | — | 19 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.97 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 HROWHarrow Health, Inc. | $1.3B | $33.60 | $66.50 | +97.9% | Buy | — | 10 |
 SGHTSight Sciences, Inc. | $462M | $8.50 | $7.00 | -17.6% | Buy | — | 9 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 RCKTRocket Pharmaceuticals, Inc. | $330M | $3.02 | $9.00 | +198.0% | Buy | — | 19 |
 REPLReplimune Group, Inc. | $1.1B | $12.96 | $18.67 | +44.1% | Buy | — | 15 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.37 | $59.50 | +144.2% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $413M | $2.69 | $4.00 | +48.7% | Buy | — | 25 |
 CRSPCRISPR Therapeutics AG | $5.4B | $55.76 | $67.83 | +21.6% | Buy | — | 38 |
Quick answers to the most common questions about buying KALA stock.
The consensus Wall Street price target for KALA is $18.25, representing 3158.9% upside from the current price of $0.56. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KALA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $18.25 implies 3158.9% upside from current levels.
KALA's current price is $0.56 with a consensus target of $18.25 (3158.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $35 for KALA, while the most conservative target is $1.5. The consensus of $18.25 represents the median expectation. These targets typically reflect 12-month expectations.
KALA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KALA stock forecast based on 9 Wall Street analysts shows a consensus price target of $18.25, with estimates ranging from $1.5 (bear case) to $35 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on KALA, with a "Buy" consensus rating and $18.25 price target (3158.9% upside). 5 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KALA analyst price targets range from $1.5 to $35, a 184% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.